We have located links that may give you full text access.
Sacrococcygeal teratoma growth rate predicts adverse outcomes.
Journal of Pediatric Surgery 2014 June
PURPOSE: The purpose of this study was to characterize the growth rate of sacrococcygeal teratomas (SCTs) and determine its relationship to adverse outcomes.
METHODS: A retrospective review of all pathology-confirmed isolated SCT patients evaluated with at least two documented ultrasounds and followed through hospital discharge between 2005 and 2012 was conducted. SCT growth rate was calculated as the difference between tumor volumes on a late- and early-gestation ultrasound divided by the difference in time. Outcomes were death, high-output cardiac failure (HOCF), hydrops, and preterm delivery. Student's t-test, receiver operator characteristics, Fisher's Exact test, and Pearson's correlation were performed.
RESULTS: Of the 28 study subjects, there were 3 in utero demises and 2 neonatal deaths. Significantly faster SCT growth rates were seen in all adverse outcomes, including death (p<0.0001), HOCF (p=0.005), and preterm delivery (p=0.009). There was a significant association with adverse outcomes at >61cm(3)/week (AUC=0.87, p=0.001, LR=4.52). Furthermore, there was an even greater association with death at >165cm(3)/week (AUC=0.93, p=0.003, LR=18.42). Growth rate was directly correlated with the percent of solid tumor (r=0.60, p=0.0008).
CONCLUSION: Faster SCT growth is associated with adverse outcomes. SCT growth rate determined by ultrasound is an effective prognostic indicator for adverse outcomes and easily applied to patient management.
METHODS: A retrospective review of all pathology-confirmed isolated SCT patients evaluated with at least two documented ultrasounds and followed through hospital discharge between 2005 and 2012 was conducted. SCT growth rate was calculated as the difference between tumor volumes on a late- and early-gestation ultrasound divided by the difference in time. Outcomes were death, high-output cardiac failure (HOCF), hydrops, and preterm delivery. Student's t-test, receiver operator characteristics, Fisher's Exact test, and Pearson's correlation were performed.
RESULTS: Of the 28 study subjects, there were 3 in utero demises and 2 neonatal deaths. Significantly faster SCT growth rates were seen in all adverse outcomes, including death (p<0.0001), HOCF (p=0.005), and preterm delivery (p=0.009). There was a significant association with adverse outcomes at >61cm(3)/week (AUC=0.87, p=0.001, LR=4.52). Furthermore, there was an even greater association with death at >165cm(3)/week (AUC=0.93, p=0.003, LR=18.42). Growth rate was directly correlated with the percent of solid tumor (r=0.60, p=0.0008).
CONCLUSION: Faster SCT growth is associated with adverse outcomes. SCT growth rate determined by ultrasound is an effective prognostic indicator for adverse outcomes and easily applied to patient management.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app